Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHAR 409 > Presentation Stuff > Flashcards

Presentation Stuff Flashcards

1
Q

Prolia: Indication

A

Osteoporosis in men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prolia: MOA

A

RANK ligand (RANKL) inhibitor > prevents formation of osteoclasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prolia: dosing freq

A

one injection q6 mths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prolia: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prolia: Place in tx

A

EDS: used if failed bisphosphonates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prolia: AEs

A

nasopharyngitis, back pain (bone-related), arthralgia (bone-related)

HTN (less common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prolia: cost

A

More than bisphosphonates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Insulin glargine: indication

A

T1/T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Insulin glargine: MOA

A

mimics body’s basal insulin release > stimulates glucose uptake and inhibits hepatic glucose production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Insulin glargine: dosing freq

A

qd @ same time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Insulin glargine: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Insulin glargine: AEs

A

nasopharyngitis, URTI, diarrhea, hypoglycemia (less common w/ LA insulins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Insulin glargine: cost

A

cheaper than Lantus (and more effective than it fyi)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Praluent: indication

A

for familial hypercholesterolemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Praluent: MOA

A

binds to PCSK9 enzymes > reduces degradation of LDL receptors > increased LDL binding and removal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Praluent: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Praluent: place in tx

A

adjunct to high-dose statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Actemra: indication

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Actemra: MOA

A

binds IL-6 receptors > inhibits their signalling > reduces inflammation in joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Actemra: route

A

IV/SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Actemra: place in tx

A

EDS:

  1. mod-sev RA as monotx or in combo w/ methotrexate or other DMARDs
  2. failed DMARDs (dz modifying antirheumatic drugs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Infliximab: indication

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Infliximab: MOA

A

binds to TNF-a > inhibits its activity > autoimmune response and inflammation are mitigated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Infliximab: route

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Infliximab: place in tx

A

reserved for pts who’ve exhaused first-line tx’s for their UC

26
Q

Benlysta: indication

A

systemic lupus erythematosus (i.e. lupus)

27
Q

Benlysta: MOA

A

binds to B cell stimulator > B cell death > unable to differentiate into plasma cells > reduced Ig production > reduced autoimmune response

28
Q

Benlysta: route

A

IV/SC

29
Q

Interferon beta-1A: indication

A

MS (relapsing-remitting MS, high risk of progression to MS)

30
Q

Interferon beta-1A: MOA

A

blocks action + entry of immune cells > reduced damage to myelin

31
Q

Interferon beta-1A: Place in tx

A

1st line for pts with relapsing-remitting MS

32
Q

Eylea: indication

A

Age-related macular degeneration (AMD) > The WET form

33
Q

Eylea: MOA

A

VEGF decoy inhibitor > intercepts VEGF-A > prevents it from binding to VEGF receptors on blood vessels in the macula > new blood vessels are prevented from growing

34
Q

Eylea: route

A

intravitreal

35
Q

Eylea: AEs

A

conjunctival hemorrhage, cataracts, eye pain

36
Q

Eylea: cost

A

cheaper than ranibizumab, but more expensive than bevacizumab

37
Q

Praxbind: indication

A

antidote for dabigatran overdose

38
Q

Praxbind: MOA

A

mAB that binds to dabigatran w/ 300x more affinity than thrombin > creates a complex that gets eliminated

39
Q

Praxbind: administration

A

two 2.5g bolus doses is given no more than 15 mins apart from e/o

40
Q

Praxbind: route

A

IV

41
Q

Praxbind: place in tx

A

ONLY antidote for a NOAC

42
Q

Yervoy: indication

A

unresectable, metastatic melanoma

43
Q

Yervoy: MOA

A

mAB that binds and blocks cytotoxic T-lymphocyte antigen 4 (which downregulates the immune sys) > upregulation of the immune system results (cytotoxic T cells, specifically, increase their activity)

44
Q

Gardasil 9: indication

A

vaccine for HPV (and subsequent cervical, vaginal, vulvar, and anal cancers, as well as genital warts

45
Q

Gardasil 9: MOA

A

Virus-like particles stimulate immune system > protective Abs against the L1 protein to prevent it from releasing its genetic material

46
Q

Gardasil 9: Dosing

A

2-3 doses given at 0, 2, and 6 mths

47
Q

Gardasil 9: route

A

IM

48
Q

Soliris: indication

A

atypical hemolytic uremic syndrome

49
Q

Soliris: MOA

A

inhibition of complement sys > reduction of microvascular stress and renal injury

50
Q

Soliris: place in tx

A

ONLY tx for atypical hemolytic uremic syndrome

51
Q

Omnitrope: indication

A

tx of growth failure in pediatrics w/ Turner’s syndrome (one missing X chromosome in females)

52
Q

Omnitrope: MOA

A

recombinant human growth hormone > binds to GH receptors on target cell membranes > skeletal growth, cell growth, protein synthesis, metabolic processes

53
Q

Omnitrope: place in tx

A

standard of care in those w/ GH deficiencies (like Turner syndrome pts)

54
Q

Omnitrope: Why does cost vary?

A

Because it’s weight-based dosing

55
Q

Herceptin: indication

A

HER2 positive breast cancer

56
Q

Herceptin: MOA

A

binds extracellular domain of HER2 protein > blocks downstream signaling pathways > inhibits cell proliferation and flags cell for destruction by immune sys

57
Q

Botox: indication

A

urge incontinence (overactive bladder)

58
Q

Botox: MOA

A

blocks ACh release at neuromuscular junction > causes paralysis muscle paralysis when injected in detrusor muscle

59
Q

Botox: Dosing

A

max 4 doses/year at least 12 weeks apart

60
Q

Botox: route

A

intradetrusor

PHAR 409 (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions